BACKGROUND: Cancer of the ampulla of Vater kills 60% of affected patients. Local spread of the tumour (T stage) is the only reliable prognostic factor. Nevertheless, any cancer stage includes long term survivors and patients dying from the disease. The molecular anomalies involved in this process have the potential to serve as additional prognostic markers. AIM: To evaluate if allelic losses (LOH) of chromosomes 17p and 18q may be of prognostic value in multivariate survival analysis. METHODS: We examined 53 ampullary cancers for chromosome 17p and 18q LOH using microsatellite markers and DNA from paraffin embedded tumours. All patients were treated by surgery alone (pancreaticoduodenectomy). Multivariate survival analysis included age, sex, tumour size, macroscopic appearance, grade of differentiation, T stage, lymph node metastasis, and chromosome 17p and 18q status. RESULTS: Chromosome 17p and 18q LOH were detected in 28 (53%) and 18 (34%) cancers, respectively. Multivariate survival analysis indicated chromosome 17p status as an independent prognostic factor together with T stage. The five year survival for chromosome 17p retention and 17p loss was 80% and 7%, respectively. The risk of death from cancer within the five year follow up period for patients with cancers harbouring chromosome 17p LOH was 11 times higher than that of patients with cancers retaining chromosome 17p (p<0.0001), regardless of the tumour stage at diagnosis. CONCLUSIONS: Chromosome 17p status is an independent prognostic factor among ampullary cancers at the same stage. The combined use of T stage and chromosome 17p status may help in deciding whether ampullary cancer patients require additional therapy other than surgery alone.
BACKGROUND:Cancer of the ampulla of Vater kills 60% of affected patients. Local spread of the tumour (T stage) is the only reliable prognostic factor. Nevertheless, any cancer stage includes long term survivors and patients dying from the disease. The molecular anomalies involved in this process have the potential to serve as additional prognostic markers. AIM: To evaluate if allelic losses (LOH) of chromosomes 17p and 18q may be of prognostic value in multivariate survival analysis. METHODS: We examined 53 ampullary cancers for chromosome 17p and 18q LOH using microsatellite markers and DNA from paraffin embedded tumours. All patients were treated by surgery alone (pancreaticoduodenectomy). Multivariate survival analysis included age, sex, tumour size, macroscopic appearance, grade of differentiation, T stage, lymph node metastasis, and chromosome 17p and 18q status. RESULTS: Chromosome 17p and 18q LOH were detected in 28 (53%) and 18 (34%) cancers, respectively. Multivariate survival analysis indicated chromosome 17p status as an independent prognostic factor together with T stage. The five year survival for chromosome 17p retention and 17p loss was 80% and 7%, respectively. The risk of death from cancer within the five year follow up period for patients with cancers harbouring chromosome 17p LOH was 11 times higher than that of patients with cancers retaining chromosome 17p (p<0.0001), regardless of the tumour stage at diagnosis. CONCLUSIONS: Chromosome 17p status is an independent prognostic factor among ampullary cancers at the same stage. The combined use of T stage and chromosome 17p status may help in deciding whether ampullary cancerpatients require additional therapy other than surgery alone.
Authors: E Martínez-López; A Abad; A Font; M Monzó; I Ojanguren; A Pifarré; J J Sánchez; C Martín; R Rosell Journal: Gastroenterology Date: 1998-06 Impact factor: 22.682
Authors: L A Aaltonen; P Peltomäki; F S Leach; P Sistonen; L Pylkkänen; J P Mecklin; H Järvinen; S M Powell; J Jen; S R Hamilton Journal: Science Date: 1993-05-07 Impact factor: 47.728
Authors: A Scarpa; P Capelli; G Zamboni; T Oda; K Mukai; F Bonetti; G Martignoni; C Iacono; G Serio; S Hirohashi Journal: Am J Pathol Date: 1993-04 Impact factor: 4.307
Authors: J Jen; H Kim; S Piantadosi; Z F Liu; R C Levitt; P Sistonen; K W Kinzler; B Vogelstein; S R Hamilton Journal: N Engl J Med Date: 1994-07-28 Impact factor: 91.245
Authors: P Peltomäki; R A Lothe; L A Aaltonen; L Pylkkänen; M Nyström-Lahti; R Seruca; L David; R Holm; D Ryberg; A Haugen Journal: Cancer Res Date: 1993-12-15 Impact factor: 12.701
Authors: D Santini; G Tonini; F M Vecchio; D Borzomati; B Vincenzi; S Valeri; A Antinori; F Castri; R Coppola; P Magistrelli; G Nuzzo; A Picciocchi Journal: J Clin Pathol Date: 2005-02 Impact factor: 3.411
Authors: Patrick S Moore; Edoardo Missiaglia; Stefania Beghelli; Emma Bragantini; Maria M Mina; Giuseppe Zamboni; Massimo Falconi; Aldo Scarpa Journal: J Cancer Res Clin Oncol Date: 2004-03-16 Impact factor: 4.553
Authors: P S Moore; S Orlandini; G Zamboni; P Capelli; G Rigaud; M Falconi; C Bassi; N R Lemoine; A Scarpa Journal: Br J Cancer Date: 2001-01 Impact factor: 7.640
Authors: Claudio Luchini; Lodewijk A A Brosens; Laura D Wood; Deyali Chatterjee; Jae Il Shin; Concetta Sciammarella; Giulia Fiadone; Giuseppe Malleo; Roberto Salvia; Valentyna Kryklyva; Maria L Piredda; Liang Cheng; Rita T Lawlor; Volkan Adsay; Aldo Scarpa Journal: Gut Date: 2020-04-29 Impact factor: 31.793